Paris, France – iPSirius today announced its decision to focus on advanced non-small cell lung cancer as the first indication for its comprehensive stem cell-based immunotherapy in the inaugural first-in-human clinical trial. Furthermore, the company declared its intention to apply for a clinical trial licence and undertake the clinical trial in the United Kingdom, to leverage the integrated clinical infrastructure, there, as well as take advantage of the country’s extensive biotech expertise and the UK government’s commitment to innovative healthcare solutions.
This decision culminated after a comprehensive road trip during which the team interfaced with prospective investors, refining the firm’s strategic trajectory in the process. Dr Stephen Sullivan, the COO of iPSirius, shared, “Our journey was illuminated by extensive dialogues with potential investors. Moreover, the astute analysis by the Health Economics and Market Access team at the Cell and Gene Therapy Catapult on IPVAC 1.0’s potential impact on global healthcare was instrumental in steering our path.”
“We’ve embarked on a transformative journey and choosing advanced non-small cell lung cancer for our first-in-human clinical trial stands as a testament to our dedication to making impactful strides in healthcare,” added Prof. Ali Turhan, a clinical oncologist and CMO of iPSirius.
Dr Martin Turner, Head of Policy and Public Affairs at the UK BioIndustry Association (BIA) said: “We are thrilled to see yet another proof-point for the UK’s unrivalled competitiveness in the global life sciences and biotech landscape. The arrival of iPSirius, a French biotech company, to conduct its first-in-human trial here demonstrates the strength of the UK research and innovation ecosystem and supportive business environment. This milestone achievement further solidifies the UK’s position as a leading destination for cutting-edge research and development, attracting top-tier talent and fostering groundbreaking collaborations. We warmly welcome iPSirius to the UK and look forward to watching their progress and contribution to our vibrant life sciences ecosystem.”
Further bolstering its position in the global biotech arena, iPSirius is proud to announce that it has secured patents for its groundbreaking immunotherapy technology, IPVAC 1.0, in both Japan and Israel. These two nations are esteemed as global powerhouses in stem cell research and development. This achievement marks a further expansion of iPSirius’s patent portfolio, now comprising 29 patents across 13 jurisdictions, underlining its unwavering commitment to leading innovation in immunoncology.
“Our secured patents in Japan and Israel signify our dedication to global collaboration,” Dr Sullivan added. “These countries are renowned for their cutting-edge advancements in stem cell research and development. We look forward to engaging colleagues and building global teams to allow the efficient translation of IPVAC 1.0 and it’s use in the fight against aggressive cancers.”
About iPSirius:
iPSirius is a French-headquartered immunoncology company dedicated to the development of cutting-edge immunotherapies for aggressive cancers. iPSirius’ technology is founded on key transcriptional and epigenetic similarities between cancer stem cells and induced pluripotent stem cells (iPS cells). With a strong focus on leveraging the power of the immune system, iPSirius aims to provide innovative treatment options for patients facing limited therapeutic alternatives. The company’s groundbreaking therapeutic product, IPVAC1.0, holds significant promise in the fight against aggressive cancer.
The company is further excited to announce that they will be presenting at several key international events in the upcoming months, which include:
- Advanced Therapies Europe in Estoril, Portugal (5-7th September 2023)
- IMAPAC Cell and Gene Therapy World Summit in London (4-5th October 2023)
- Fierce Biotech Summit in Boston (16-18th October 2023)
- BIO-Europe in Munich (6th-8th November 2023)
- Advanced Therapies Congress & Expo in London (19th & 20th March 2024)